The ANRIL gene is involved in atherosclerotic processes and acute myocardial infarction (AMI) initiation. The rs1333040 polymorphism shows potential association with coronary artery lesions and cardiovascular events in AMI patients, though data remains limited. To determine the prognostic value of the rs1333040 ANRIL gene polymorphism for coronary artery lesions and cardiovascular events in AMI patients. A cross-sectional descriptive study with longitudinal follow-up, conducted at the Interventional Cardiology Department of Can Tho Central General Hospital from October 2022 to June 2024. AMI patients underwent clinical examination, genetic sequencing, and cardiovascular event monitoring. Among 150 patients (mean age 63.8 ± 10.3 years, 70.7 % male), genotype distribution showed TT as the most prevalent (55.3 %), TC (38.7 %), and CC (6.0 %). Diabetes mellitus was more prevalent in the TT genotype (28.9 %) versus TC (12.1 %) and CC (11.1 %). Severe coronary artery lesions were more common in TT genotype patients (65.7 % vs. 45.4 %; p < 0.05), with the T allele identified as a risk allele (OR = 2.22; 95 % CI: 1.29–3.81; p < 0.05). Multi-vessel coronary artery disease (CAD) was also more frequent in TT genotype patients (59.8 % vs. 49.2 %; p < 0.05). At the 9-month follow-up, event rates were: mortality 4.0 %, stroke 0.7 %, HF hospitalization 6.0 %, and MACE 10.7 %. Independent predictors for MACE initiation included age (HR = 1.05), diabetes (HR = 2.98), TT genotype (HR = 3.63), and T allele (HR = 3.39). AMI patients with the T allele of the rs1333040 ANRIL gene show more severe coronary lesions, higher multi-vessel disease risk, and poorer prognosis with increased MACE event probability.
Background Coronary artery disease (CAD) and acute myocardial infarction (AMI) are substantial contributors to the global disease burden and mortality. The ANRIL gene polymorphism rs1333040 has been implicated in susceptibility to cardiovascular disease; however, its role in the Vietnamese population remains unclear. Methods A cross-sectional study was conducted on 185 Vietnamese patients diagnosed with acute coronary syndrome (ACS), and clinical data, medical history, and biochemical parameters were recorded. ANRIL SNP rs1333040 was genotyped using PCR-RFLP. Genotype frequencies were assessed for Hardy-Weinberg equilibrium and their association with cardiovascular risk factors. Results The ‘Normal’ BMI (Body Mass Index) category was the largest segment, comprising 77.84% of the sample. Key cardiovascular risk factors identified among patients with AMI included hypertension (83.8%), dyslipidemia (80.0%), smoking (50.0%), and diabetes mellitus (33.8%). Clinical presentation showed that 55.0% of patients had non-ST-elevation myocardial infarction (NSTEMI) and 45.0% had ST-elevation myocardial infarction (STEMI). Lipid profile abnormalities were significant; 60.0% had decreased High-Density Lipoprotein Cholesterol (HDL-C), 53.8% had elevated triglycerides, 37.5% had elevated Low-Density Lipoprotein Cholesterol (LDL-C), and 36.3% had elevated total cholesterol levels. Genetic analysis focused on the rs1333040 polymorphism of the ANRIL gene, with the most common genotype being TT (58.8%), followed by CT (33.7%) and CC (7.5%). Allele frequencies were 75.6% for T and 24.4% for C. This study is the clinical implications of ANRIL polymorphisms in Vietnamese patients with CAD and AMI. Significant genotype-phenotype associations were observed, underscoring the importance of incorporating genetic screening for enhanced prognostic capabilities and personalized therapeutic decisions. Further research focused on delineating the precise genetic underpinnings of complex cardiovascular diseases in diverse populations is warranted.
Background: There have not been many studies evaluating the results of Diacerein treatment in patients with knee osteoarthritis (OA) and obesity, particularly comparing dosage levels of 50 and 100 mg/day. Methods: A randomized, single-blind, noncontrolled clinical trial was conducted at the Ho Chi Minh City Hospital for Rehabilitation, Vietnam, from January 2023 to January 2024. Patients with odd-numbered records received Diacerein 50 mg/day, while those with even-numbered records received 100 mg/day. Primary outcomes included symptom and functional improvements, assessed using visual analogue scale (VAS) and Western Ontario and McMaster University Osteoarthritis (WOMAC) scores at weeks 4 and 8. Results: A total of 256 patients (average age 58.3 ± 12.0 years; 59.4% female) were included, and 53.1% reported moderate pain, with average VAS and WOMAC scores of 64.7 ± 14.4 mm and 51.7 ± 11.4 points, respectively. Increased waist circumference, triglycerides (TG), and TG/high density of lipoprotein cholesterol ratio were identified as risk factors for severe knee OA, with respective odds ratio of 4.9 (1.6–14.7), 47 (12.5–176.1), and 22.5 (6.7–75.9). Diacerein significantly improved symptoms and joint function, with the 100-mg/day group showing faster and greater average reductions in VAS and WOMAC scores at weeks 4 and 8. The most notable reduction was 26.7 ± 11.3 for VAS and 20.7 ± 8.9 for WOMAC in week 4. Conclusion: Increased waist circumference, plasma TG, and TG/high density of lipoprotein cholesterol ratio raise the risk of severe knee OA. Diacerein treatment improves symptoms and joint function in patients with knee OA accompanied by obesity, with the 100-mg/day dose showing earlier and more effective improvement than the 50-mg/day dose.